Last reviewed · How we verify
KYN-5356
At a glance
| Generic name | KYN-5356 |
|---|---|
| Sponsor | Kynexis B.V. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia (PHASE2)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KYN-5356 CI brief — competitive landscape report
- KYN-5356 updates RSS · CI watch RSS
- Kynexis B.V. portfolio CI